Efficient treatment of murine systemic infection with Candida albicans using amphotericin B incorporated in nanosize range particles (emulsomes)

Mycoses

Volumn 44, Issue 7-8, 2001, Pages 281-286

  Kretschmar, Marianne ^a,c   Amselem, S ^b   Zawoznik, E ^b   Mosbach, K ^a   Dietz, A ^a   Hof, H ^a   Nichterlein, T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b PHARMOS LTD   (Israel)

^c Inst fur Medizinische Mikrobiol/H   (Germany)

Author keywords

Amphotericin B; Antimycotic chemotherapy; Candida albicans; Liposomes; Nanosize particles; Systemic infection

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DEOXYCHOLIC ACID; ISOTONIC SOLUTION; LIPID;

ANIMAL CELL; ARTICLE; CANDIDA ALBICANS; CANDIDIASIS; CONTROLLED STUDY; IN VIVO STUDY; KIDNEY; LIVER; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE CULTURE;

AMPHOTERICIN B; ANIMALS; ANTIBIOTICS, ANTIFUNGAL; CANDIDA; CANDIDIASIS; CELL CULTURE TECHNIQUES; FEMALE; FUNGEMIA; INTERLEUKINS; LIPIDS; LIPOSOMES; MICE; MICE, INBRED BALB C; MICROBIAL SENSITIVITY TESTS; SUSPENSIONS; TISSUE DISTRIBUTION;

ANIMALIA; CANDIDA; CANDIDA ALBICANS; MURINAE;

EID: 0035788140     PISSN: 09337407     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1439-0507.2001.00654.x     Document Type: Article

References (19)

1. Gyanchandani, A., Khan, Z. K., Farooqui, N., Goswami, M. & Ranade, S. A. (1998) RAPD analysis of Candida albicans strains recovered from different immunocompromised patients (ICP) reveals an apparently non-random infectivity of the strains. Biochem. Mol. Biol. Int. 44, 19-27.
2. Holmberg, K. & Meyer, R. D. (1986) Fungal infections in patients with AIDS and AIDS-related complex. Scand. J. Infect. Dis. 18, 179-192.
3. Schaberg, D. R., Culver, D. H. & Gayner, R. P. (1991) Major trends in the microbial etiology of nosocomial infection. Am. J. Med. 16, 72-75.
4. Edwards, J. E. Jr., Bodey, G. P., Bowden, R. A., et al. (1997) International Conference for the development of a consensus on the management and prevention of severe candidal infections. Clin. Infect. Dis. 25, 43-59.
5. Hiemenz, J. W. & Walsh, T. J. (1996) Lipid formulations of amphotericin B: recent progress and future directions. Clin. Infect. Dis. 22 (Suppl. 2), S133-S144.
6. Wong-Beringer, A., Jacobs, R. A. & Guglielmo, B. J. (1998) Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 27, 603.
7. Santhi, K., Dhanaraj, S. A., Rajendran, S. D., Raja, K., Ponnusankar, S. & Suresh, B. (1999) Nonliposomal approach - a study of preparation of egg albumin nanospheres containing amphotericin-B. Drug. Dev. Ind. Pharm. 25, 547-551.
8. Espuelas, M. S., Legrand, P., Irache, J. M., et al. (1997) Poly (ε-caprolacton) nanoparticles as an alternative way to reduce amphotericin B toxicity. Int. J. Pharm. 158, 19-27.
9. Sen, N., Samanta, A., Baidya, S., Gupta, B. K. & Ghosh, L. K. (1998) Development of amphotericin B loaded nanoparticles. Boll. Chim. Farm. 137, 295-297.
10. Otsubo, T., Maesaki, S., Hossain, M. A., et al. (1999) In vitro and in vivo activities of NS-718, a new lipid nanosphere incorporating amphotericin B, against Aspergillus fumigatus. Antimicrob. Agents Chemother. 42, 471-475.
11. Hossain, M. A., Maesaki, S., Kakeya, H., et al. (1998) Efficacy of NS-718, a novel lipid nanosphere-encapsulated amphotericin B, against Cryptococcus neoformans. Antimicrob. Agents Chemother. 42, 1722-1725.
12. Amselem, S. & Friedman, D. (1996, 1997) US Patents 5,576,016 and 5,662,932.
13. National Committee for Clinical Laboratory Standards. (2000) Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts. Approved Standard M27-A. Wayne, PA, USA: National Committee for Clinical Laboratory Standards.
14. Nichterlein, T., Kretschmar, M., Budeanu, C., Bauer, J. & Linss, W. (1994) Bay Y 3118, a new quinolone derivative, rapidly eradicates Listeria monocytogenes from infected mice and L929 cells. Antimicrob. Agents Chemother. 38, 1501-1506.
15. Amselem, S., Yogev, A., Zawwoznik, E. & Friedman, D. (1994) Emulsomes, a novel drug delivery technology. Proceedings of the 21st International Symposium on Controlled Release of Bioactive Materials. Nice, France, June 27-30, 1994, pp. 668-669. The Controlled Release Society, Inc.
16. Proffitt, R. T., Satorius, R. P., Chiang, S. M., Sullivan, L. & Adler-Moore, J. P. (1991) Pharmacology and toxicology of a liposomal formulation of amphotericin B (AmBisome) in rodents. J. Antimicrob. Chemother. 28 (Suppl. B), 49-61.
17. Wasan, K. M. & Lopez-Berestein, G. (1996) Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients. Clin. Infect. Dis. 23, 1126-1138.
18. Kretschmar, M., Nichterlein, T., Hannak, D. & Hof, H. (1996) Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Arzneimittel-Forschung/ Drug Res. 46, 711-715.
19. Gregoriadis, G. (1988) Fate of injected liposomes: observations on entrapped solute retention, vesicle clearance and tissue distribution in vivo. In: Gregoriadis, G. (ed.) Liposomes as Drug Carriers: Recent Trends and Progress. Chichester, UK: John Wiley, pp. 3-11.